新药分享 | 肺癌免疫治疗的的新标杆——斯鲁利单抗 数十年来,基于铂类联合依托泊苷或伊立替康的化疗仍然是广泛期小细胞肺癌(ES-SCLC)的标准一线治疗方案,但患者预后相对较差,中位总生存期普遍不长。 研发新型治疗药物、探索新型治疗模式,让小细胞肺癌患者有更好的生存获益是医学界的课题。 终于,我们迎来了重磅...
8561 Background: Atezolizumab plus chemotherapy was the first CIT combination regimen approved for 1L treatment of ES-SCLC in 2019. This study investigated patient characteristics and treatment patterns for patients with ES-SCLC receiving this regimen in the real-world community oncology setting. Methods...
MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIANdoi:10.1016/j.jtho.2021.08.198M. GarassinoY. ShresthaM. XieZ. LaiS. SpencerT. DalviL. Paz-AresJournal of Thoracic Oncology...
(例如,toposar,vepesid),依托泊苷磷酸盐(例如,etopophos)、依维莫司(例如,afinitordisperz、afinitor)、依西美坦(例如,aromasin)、fec、氟达拉滨磷酸盐(例如,fludara)、氟尿嘧啶(例如,adrucil、efudex、fuflex)、folfiri、folfiri‑bevacizumab、folfiri‑西妥昔单抗、folfirinox、folfox、fu‑lv、氟维司群(...
该研究由程颖教授和中国医学科学院肿瘤医院王洁教授共同担任主要研究者,全国47家医院共同参与,旨在评估PD-L1抑制剂阿得贝利单抗联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)的疗效和安全性。 打开APP,查看更多精彩图片 本次公布的数据显示,相较于安慰剂联合化疗...查看全文...
Background: The IMpower133 represented the current standard of care in the 1L setting for patients (pts) with ES-SCLC (extensive-stage small cell lung cancer). However, there are still unmet needs for ES-SCLC treatment. LDRT could play a key role in the priming effect of immune system by...
49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)doi:10.1093/annonc/mdy486Califano, RKażarnowicz, AKaraseva, N...
智通财经APP获悉,6月2日,先声药业(02096)与海南博鳌恒大国际医院宣布,曾获FDA突破性疗法认定的新药Trilaciclib,已经获得海南省药品监督管理局的批准,在博鳌乐城国际医疗旅游先行区进行临床应用,并在博鳌恒大国际医院开出国内首张处方,完成了对广泛期小细胞肺癌患者(ES-SCLC)的首次临床给药。
A multicenter, single-arm phase II study was conducted to evaluate the efficacy and safety of surufatinib (a small-molecule inhibitor of VEGFR 1-3, FGFR1 and CSF-1R) combined with PD-1/L1 inhibitors in pts with ES-SCLC as 1L maintenance therapy.Methods:Key inclusion criteria were ...
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIANdoi:10.1016/j.annonc.2020.08.2328J.W. GoldmanM.C. Garassino...